IMP Monthly Report | November 2020
Wow, what a month global markets had in November. The confluence of multiple highly successful Phase 3 COVID-19 vaccine trials, combined with increased Central Bank stimulus (locally), and relief over the outcome of the US elections, drove the best performance in decades.
In Australia, we must measure November’s gains against the All Ordinaries Index because the younger S&P/ASX 200 Index has simply never delivered a rally that large. For the record, the All Ords rose 9.93% (its best since May 1988), and only narrowly missed a double-digit gain due to a last-minute pull back on November 30th.
Australia’s gains were comparable (especially if considered alongside a 4.5% appreciation in the $AUD) to overseas markets with the Dow Jones Industrial Average and Nasdaq Composite each delivering 11.8%, London’s FTSE 12.4%, and both Japan’s Nikkei and German DAX posting 15% gains for the month.
This was a global rally of historic proportions, and what was perhaps the most pertinent element was the underlying nature of the gains… Continue through to the full report here.
The links below will take you to the October 2020 Holdings & Yield Forecast charts for each of our portfolios:
IMP 100I | a model portfolio designed to more for income than growth with the majority of the funds invested in the top 100 ASX listed companies
IMP 100T | a model portfolio designed to more for growth than income with the majority of the funds invested in the top 100 ASX listed companies
IMP 200 | a model portfolio designed with the majority of the funds invested in the top 200 ASX listed companies
IMP 300 | a model portfolio designed with the majority of the funds invested in the top 300 ASX listed companies
YMP | a model portfolio designed for income with the majority of the funds invested in the top 100 ASX listed companies
For more information about our Individually Managed Portfolios, contact us to speak to one of our specialists.